Chronic Fatigue Syndrome Disease

BASICS

DESCRIPTION
Chronic fatigue syndrome (CFS) is characterized primarily by profound fatigue, in association with multiple systemic and neuropsychiatric symptoms, lasting at least 6 months. The fatigue must have a new or definite onset (i.e., not lifelong), is not relieved by rest, and results in a substantial reduction in previous activities (occupation, education, social, and personal).
  • System(s) affected: Endocrine/Metabolic, Musculoskeletal
  • Genetics: N/A
  • Incidence/Prevalence in USA: 10/100,000
  • Predominant age: Young adult
  • Predominant sex: Female > Male (slightly)
SIGNS AND SYMPTOMS
  • Fatigue (100%)
  • Ability to date onset of illness (100%)
  • Unexplained general muscle weakness (90%)
  • Arthralgias (90%)
  • Forgetfulness (90%)
  • Inability to concentrate (90%)
  • Emotional lability (90%)
  • Myalgias (90%)
  • Confusion (90%)
  • Mood swings (90%)
  • Low-grade fever (37.5-38.6°C) (85%)
  • Irritability (85%)
  • Prolonged fatigue lasting 24 hours after exercise (80%)
  • Depression (80%)
  • Headaches (76%)
  • Photophobia (76%)
  • Difficulty sleeping (76%)
  • Allergies (70%)
  • Vertigo (40%)
  • Adenopathy (40%)
  • Shortness of breath (33%)
  • Chest pain (33%)
  • Nausea (33%)
  • Weight loss (30%)
  • Hot flushes (30%)
  • Palpitations (30%)
  • Painful lymph nodes (30%)
  • Gastrointestinal complaints (30%)
  • Night sweats (25%)
  • Weight gain (15%)
  • Rash (15%)
CAUSES
Unknown. Multiple immunologic abnormalities suggestive of viral reactivation syndrome have been reported. Attention has been to viruses (EBV, HHV-6, enteroviruses), possibly in concert, possibly with environmental factors. No infectious agent has been implicated in the syndrome.
RISK FACTORS
Unknown

DIAGNOSIS

LABORATORY
  • Initial lab studies
    • Chemistry panel
    • CBC
    • Urinalysis
    • Thyroid function
  • Additional studies
    • ESR
    • ANA
    • VDRL
    • Rheumatoid factor
    • Purified protein derivative
    • Serum cortisol
    • HIV
    • Immunoglobulin
    • Epstein-Barr serology


Drugs that may alter lab results: N/A
Disorders that may alter lab results: N/A

PATHOLOGICAL FINDINGS
N/A
SPECIAL TESTS
None. Diagnosis of exclusion. History, physical exam normal.
IMAGING
Experimental at present
DIAGNOSTIC PROCEDURES
To establish the diagnosis - 2 major criteria and at least 6 symptoms plus at least 2 physical signs; or at least 8 symptoms
  • Major criteria:
    • New onset fatigue lasting longer than 6 months with a 50% reduction in activity
    • No other medical or psychiatric conditions that could cause symptoms
  • Symptoms:
    • Low grade fever
    • Sore throat
    • Painful cervical or axillary adenopathy
    • Generalized muscle weakness
    • Myalgias
    • Headaches
    • Migratory arthralgias
    • Sleep disturbances (hypersomnia or insomnia)
    • Neuropsychological complaints (one or more of: photophobia, visual scotomas, forgetfulness, irritability, confusion, difficulty concentrating, depression)
  • Physical signs:
    • Low grade fever (37.5-38.6°C)
    • Pharyngitis (nonexudative)
    • Cervical or axillary adenopathy

TREATMENT

APPROPRIATE HEALTH CARE

Outpatient

GENERAL MEASURES
  • Because the cause of CFS is unknown and no specific therapy has shown consistent results, mainstay of therapy is supportive care
  • A program of moderate exercise (with rest periods during exacerbations of the disease), a healthy diet, stress reduction, and support groups or counseling is likely to be beneficial and while not necessarily curative will help the patient cope with their disease
  • Alternative therapies (chiropractic, homeopathy, acupuncture, enforced rest, guided image hypnosis) helpful for some; may be worth trying
  • Psychiatric symptoms often prominent but generally felt secondary rather than causative, but symptom treatment beneficial
SURGICAL MEASURES

N/A

ACTIVITY

As tolerated, but strenuous exercise tends to exacerbate symptoms in most

DIET

Rich in vitamins and minerals

PATIENT EDUCATION
  • Support groups available. Contact CFS Association, 3521 Broadway, Suite 222, Kansas City, MO 64111, (816)931-4777
  • CFIDS Association. P.O. Box 220398, Charlotte, NC 28222-0398
  • International Chronic Fatigue Syndrome Society. P.O. Box 230108, Portland, OR 97223

FOLLOW UP

PREVENTION/AVOIDANCE

Unknown

POSSIBLE COMPLICATIONS
  • Depression
  • Socioeconomic problems
EXPECTED COURSE AND PROGNOSIS
  • Indolent; waxes and wanes
  • Generally very slow improvement over months or years

MISCELLANEOUS

ASSOCIATED CONDITIONS
  • Fibromyalgia (70% reported to meet criteria)
  • Depression
  • Hypochondriasis
AGE-RELATED FACTORS

Pediatric: Reported in children
Geriatric: Reported in elderly
Others: N/A

PREGNANCY

No information

OTHER NOTES

Controversial topic, data often conflicting

ABBREVIATIONS

CFS = chronic fatigue syndrome

Clinical Investigations

ROLE OF HOMOEOPATHY

Copyright © 2025 Selkey. All Rights Reserved.